Oxford/AstraZeneca: Vaxzevria

Vaccine Type: Non Replicating Viral Vector

This vaccine may also be referred to as AZD1222, ChAdOx1 nCoV-19

Vaccine Trial & Approval Tracker

This vaccine is approved.

About Trial Phases

Phase 1: 10 Trials

Phase 2: 39 Trials

Phase 3: 24 Trials


Africa Regulatory Taskforce Endorsed

Caribbean Regulatory System Emergency Use Recommendation

WHO Emergency Use Listing

149 Countries

This vaccine is also manufactured by the Serum Institute of India (Covishield)

Registered Trials